News

Brentuximab vedotin is an antibody-drug conjugate (ADC) directed to CD30, a marker of classical Hodgkin lymphoma. The FDA is likely to take a call on Adcetris approval by

The Company plans to initiate these studies imminently. Tabelecleucel is Atara's off-the-shelf T-cell immunotherapy in development for the treatment of EBV+PTLD, as well as other EBV associated hematologic

The data from the study demonstrated that the three-part drug has improved certain aspects of memory and thinking ability, as well as helped in limited brain changes associated

Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated in the treatment

Atacand is an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension in adults and children 1 to <17 years of age, to lower blood pressure.

The transaction amount includes Sucampo’s debt of $360m assumed by the UK-based Mallinckrodt. Amitiza (lubiprostone) has the approvals of the US Food and Drug Administration (FDA) for three

Summit retains commercialisation rights in all other countries. Ridinilazole is a targeted antibiotic that has the potential as a frontline therapy to treat initial infection and preserve patients'

The European Commission has approved Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer, while the US Food and Drug Administration (FDA) approved Perjeta (pertuzumab), in combination with Herceptin (trastuzumab) and

Under the agreement, vTv has granted Huadong Pharmaceutical an exclusive license to develop, manufacture and commercialize vTv Therapeutics’ GLP-1r agonist program in China, Hong Kong, Macau, Taiwan, Thailand,